Interaction of Sulfonylureas with Liver Uptake Transporters OATP1B1 and OATP1B3
Authors:
Open Access
- 2 March 2018
- journal article
- abstracts
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 123 (2) , 147-154
Abstract
Sulfonylureas (SUs) such as glibenclamide, gliclazide, glimepiride, glipizide and gliquidone are one of the first oral medicines available for the treatment of type 2 diabetes and are widely used for the treatment of hyperglycaemia. The hepatic transporters, organic anion transporting polypeptide 1B1 (OATP1B1) and organic anion transporting polypeptide 1B3 (OATP1B3), play an important role in the disposition of a variety of drugs by mediating their uptake from blood into hepatocytes. Drug–drug interactions mediated by OATP1B1/1B3 may result in the hepatic transporting change for drug substrates. The inhibitory effects of glibenclamide and glimepiride on sulfobromophthalein (BSP) uptake have been previously studied, and glibenclamide has been reported as the substrate of OATP1B3, but it remains unclear whether other SUs such as gliclazide, glipizide and gliquidone are substrates of OATP1B1 and OATP1B3. Here, we investigated the relationship between the five most commonly applied SUs (glibenclamide, gliclazide, glimepiride, glipizide, gliquidone) and OATP1B1 and OATP1B3. We performed uptake and inhibition assays in HEK293T cells stably expressing OATP1B1 or OATP1B3, respectively, and established a liquid chromatography–mass spectrometry (LC‐MS) method for the simultaneous measurement of five SUs. We demonstrated that gliclazide and glimepiride are substrates of OATP1B1 and glibenclamide and glipizide are substrates of OATP1B3. We also confirmed the interaction between these SUs and rosuvastatin. No transporting was observed for gliquidone, suggesting that it is not a substrate of either transporter.Keywords
Funding Information
- National Natural Science Foundation of China (81160411, 81560606, 81760672)
This publication has 35 references indexed in Scilit:
- Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorptionBiopharmaceutics & Drug Disposition, 2013
- Characterization of Ursodeoxycholic and Norursodeoxycholic Acid as Substrates of the Hepatic Uptake TransportersOATP1B1,OATP1B3,OATP2B1 andNTCPBasic & Clinical Pharmacology & Toxicology, 2012
- Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphismsExpert Review of Cardiovascular Therapy, 2010
- Membrane transporters in drug developmentNature Reviews Drug Discovery, 2010
- Involvement of Multiple Transporters in the Hepatobiliary Transport of RosuvastatinDrug Metabolism and Disposition, 2008
- Oral Antidiabetic AgentsDrugs, 2005
- High-Level Expression of Human Inducible Nitric Oxide Synthase in Chinese Hamster Ovary Cells and Characterization of the Purified EnzymeBiochemical and Biophysical Research Communications, 1996
- Comparative Tolerability Profiles of Oral Antidiabetic AgentsDrug Safety, 1994
- Clinical Pharmacology of Oral Antidiabetic AgentsNew England Journal of Medicine, 1977
- Binding of Sulfonylureas to Serum ProteinsJournal of Pharmaceutical Sciences, 1972